Any current/future new fundraising through debt or equity?

There are no current plans for fundraising through debt or equity mentioned. The company is working on regulatory procedures related to the medical devices business but has not planned any capital event yet. Fundraising or capital raising for the medical devices segment may happen in the future at an appropriate stage, but no concrete plans are on the card currently. The company emphasizes internal accruals and aims to expand capacity and backward integration using internal resources. They are a largely debt-free company with negligible debt and have cleared all old debts. Any future capital-r

Any current/future capex/capital investment/strategic investment?

The company is actively expanding capacities, especially in medical devices and APIs, due to increasing demand. Major part of capex is directed toward building large sheds to accommodate injection molding and other machinery for backward integration in medical devices. High-speed machines with higher capacities have been installed in formulation to improve volume and profitability. Research and development investments include three labs: Okhla (biosensors), Baddi (in-house medical device production), and Bangalore (electronics). Existing gross block investments mainly cater to API and formulat

Future growth expectations in sales/revenue/volumes?

Medical Devices segment is the fastest-growing business at 28% CAGR; overall company CAGR is 16%. Planned meter sales: 30 lakh meters this year, increasing to 36 lakh and then 40 lakh meters in subsequent years. Strips per meter sold currently ~150, aiming to increase to 155+ (was 165 during COVID due to high usage). Addressable market for meters estimated at 5 crores; currently at 1 crore installed meters, targeting growth to 2-3 crores over 3-4 years. Sales growth target: around 27% CAGR for meters to double in 3 years. Revenues from Strips expected to grow proportionally with meters. Capaci

Future growth expectations in earnings/operating earnings/profits/EPS?

Company expects continued revenue growth with medical devices growing at a CAGR of 28% and overall company CAGR at 16%. EBITDA margins in devices business projected to increase to 18%-19% due to higher volumes and strip sales per meter. EBITDA grew more than 101% YoY to Rs. 173 crores; PAT increased 150% to Rs. 97 crores. EPS has nearly doubled to Rs. 1.88 on Rs. 2 share with Return on Equity improving from 5% to 11%. Formulation business targeted to reach break-even by FY25, reducing current losses. API business EBITDA margins improved to 18% from 16% YoY. Management aims to maintain healthy

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders as specific numeric values. However, it indicates plans for significant expansion: - Planned sale of 30 lakh meters this year, increasing to 36 lakh and then 40 lakh meters in subsequent years. The business expects growth in strip sales, targeting an increase from 150 to 155 strips sold per meter. The device business is anticipated to increase margin gradually over the next five years. There is mention of an expanding market opportunity, including untapped Middle Eastern and South American market

Morepen Laboratories LtdQ4 FY24Pharmaceuticals & Biotechnology

Morepen Laboratories Ltd Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹119P/E: 56.2Market Cap: ₹6.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Medical Devices segment is the fastest-growing business at 28% CAGR; overall company CAGR is 16%.
Planned meter sales: 30 lakh meters this year, increasing to 36 lakh and then 40 lakh meters in subsequent years.
Strips per meter sold currently ~150, aiming to increase to 155+ (was 165 during COVID due to high usage).
Addressable market for meters estimated at 5 crores; currently at 1 crore installed meters, targeting growth to 2-3 crores over 3-4 years.
Sales growth target: around 27% CAGR for meters to double in 3 years.
Revenues from Strips expected to grow proportionally with meters.
Capacity expansions underway with high-speed machines to meet increasing demand.
API business revenue grew 14% annually; U.S. market grew 32% recently.
Formulation & OTC businesses aim for breakeven with moderate growth (~10%).
Overall company revenue expected to maintain 20% growth, with EBITDA and margins improving alongside volume growth.

Margin guidance

Category 1

Company expects continued revenue growth with medical devices growing at a CAGR of 28% and overall company CAGR at 16%.
EBITDA margins in devices business projected to increase to 18%-19% due to higher volumes and strip sales per meter.
EBITDA grew more than 101% YoY to Rs. 173 crores; PAT increased 150% to Rs. 97 crores.
EPS has nearly doubled to Rs. 1.88 on Rs. 2 share with Return on Equity improving from 5% to 11%.
Formulation business targeted to reach break-even by FY25, reducing current losses.
API business EBITDA margins improved to 18% from 16% YoY.
Management aims to maintain healthy growth with margins expanding as volumes increase.
Devices business benefits from a “printer cartridge” model, with growing installed meters leading to higher recurring strip sales and improving margins.
Overall long-term growth driven by capacity expansion, backward integration, and market reach enhancement.

See what Morepen Laboratories Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There are no current plans for fundraising through debt or equity mentioned.
The company is working on regulatory procedures related to the medical devices business but has not planned any capital event yet.
Fundraising or capital raising for the medical devices segment may happen in the future at an appropriate stage, but no concrete plans are on the card currently.
The company emphasizes internal accruals and aims to expand capacity and backward integration using internal resources.
They are a largely debt-free company with negligible debt and have cleared all old debts.
Any future capital-raising for the devices business will depend on business needs and regulatory approvals.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders as specific numeric values.
However, it indicates plans for significant expansion:
- Planned sale of 30 lakh meters this year, increasing to 36 lakh and then 40 lakh meters in subsequent years.
The business expects growth in strip sales, targeting an increase from 150 to 155 strips sold per meter.
The device business is anticipated to increase margin gradually over the next five years.
There is mention of an expanding market opportunity, including untapped Middle Eastern and South American markets.
The company is focusing on building manufacturing capacity aiming toward a Rs. 5,000 crore scale.
No explicit order backlog numbers, but the tone suggests a growing and robust demand pipeline.

See what Morepen Laboratories Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The company is actively expanding capacities, especially in medical devices and APIs, due to increasing demand.
Major part of capex is directed toward building large sheds to accommodate injection molding and other machinery for backward integration in medical devices.
High-speed machines with higher capacities have been installed in formulation to improve volume and profitability.
Research and development investments include three labs: Okhla (biosensors), Baddi (in-house medical device production), and Bangalore (electronics).
Existing gross block investments mainly cater to API and formulation, with potential to increase topline by approximately Rs. 150-200 crores in API and 2.5-3 times in formulation over the next 1-2 years without major new CAPEX.
The company plans to start shifting medical devices business into a separate company within the financial year, which may involve new licenses and potential capital events or fundraising.
Investments are funded through internal accruals; the company remains largely debt-free.

Track Morepen Laboratories Ltd — get its next earnings analysis in your feed

How does Morepen Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisMorepen Laboratories Ltd

Rev 2Mar 1

See where Morepen Laboratories Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Morepen Laboratories Ltd rank in Pharmaceuticals & Biotechnology?

Compare Morepen Laboratories Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Morepen Laboratories Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
FDC Ltd (Q3 FY23)
Q3FY23 Revenue from operations: ₹407 crores, up 19% YoY from ₹341 crores in Q3FY22 (Page 13). Key concall takeaways from FDC Ltd's Q3 FY23 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →